Skip to main content

Sienna Biopharmaceuticals Announces $40 Million Series B Financing

Topical Biotech Innovation in Medical Dermatology and Aesthetics   Westlake Village, CA, April 24, 2017 – Sienna Biopharmaceuticals, Inc., a privately held, clinical stage medical dermatology and aesthetics company, today announced that it completed a $40 million Series B financing led by existing investors ARCH Venture Partners and Venvest Capital. Additional investors participating included Partner ... Read more »

Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals

Appointment Marks Pyott’s Return to Dermatology and Aesthetics Westlake Village, Calif. (February 28, 2017) – Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, is pleased to announce that David E.I. Pyott has signed on as special advisor to Sienna’s CEO and Board of Directors. Dr. Pyott is well known from his ... Read more »

Sienna Biopharmaceuticals Acquires Creabilis plc

Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, today announced it has acquired Creabilis plc, a privately held specialty pharmaceutical company focused on developing first-in-class topical treatments for common inflammatory skin conditions, including psoriasis, atopic dermatitis and pruritus (itch). Read more »